Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease

Area of Science:

• Biomedical Science
• Neuroscience
• Molecular Biology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, affecting millions globally.
• Current treatments for AD are limited, necessitating novel therapeutic strategies.
• Nucleic acid-based technologies offer a promising avenue for AD theranostics.

Purpose of the Study:

• To review recent developments in nucleic acid-based theranostic strategies for Alzheimer's disease.
• To highlight the potential of nucleic acids in diagnosing and treating AD.
• To discuss the significance of targeting underlying molecular causes of AD.

Main Methods:

• Comprehensive literature review of recent studies on nucleic acid-based theranostics for AD.
• Analysis of FDA-approved nucleic acid drugs (e.g., Nusinersen) for neurological disorders.
• Synthesis of current research on diagnostic and therapeutic applications of nucleic acids in AD.

Main Results:

• Nucleic acid technologies are emerging as powerful tools for AD theranostics.
• Antisense oligonucleotides and other nucleic acid modalities show potential for AD treatment.
• Advancements in nucleic acid delivery and targeting are crucial for efficacy.

Conclusions:

• Nucleic acid-based theranostics represent a significant advancement in Alzheimer's disease research.
• Further research is needed to translate these findings into effective clinical interventions for AD.
• Targeting molecular pathways with nucleic acids offers a new paradigm for AD management.